| 0.0009 -0.001 (-40%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
PAVmed Inc. functions as a medical technology enterprise based in the United States. Its primary offerings feature CarpX, a patented, single-use, disposable, and minimally invasive surgical tool developed for addressing carpal tunnel syndrome. The company also provides EsoCheck, an esophageal cell collection device facilitating the early identification of esophageal adenocarcinoma and Barrett's Esophagus (BE), along with EsoGuard, an advanced DNA assay utilizing bisulfite-converted next-generation sequencing. Moreover, the firm's developmental pipeline encompasses EsoCure, an esophageal ablation device aimed at treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and the Veris cancer care platform. Founded in 2014, the corporation initially operated under the name PAXmed Inc., subsequently adopting its current designation, PAVmed Inc., in April 2015. Its corporate headquarters are located in New York, New York.
Tue, 17 Jan 2023
PAVmed and Lucid Diagnostics Provide Strategic Business Update - Business Wire
Thu, 15 Dec 2022
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform - Business Wire
Mon, 15 Aug 2022
Lucid Diagnostics Provides Business Update - citybiz
Thu, 24 Feb 2022
PAVmed Appoints Shaun O’Neil as Chief Operating Officer - Business Wire
Tue, 16 Nov 2021
PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results - Business Wire
Mon, 25 Oct 2021
Veris Health Appoints Sunny Webb as Chief Technology Officer - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|